A Pilot Study to Determine the Efficacy of a Low Carbohydrate Diet in Treatment of Adolescents With Metabolic Syndrome
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The purpose of this study is to determine the effectiveness of two different non-energy restricted controlled carbohydrate programs with the American Diabetes Associations' diet on glycosylated hemoglobin and other diabetes risk factors in obese adolescents with metabolic syndrome, a constellation of symptoms associated with the development of type 2 diabetes and cardiovascular disease.
We plan to address the following issues:
- To test the hypothesis that a controlled carbohydrate nutrition plan will be superior to the standard ADA diet in controlling blood sugar (as measured by glycosylated hemoglobin [HbA1C]), decreasing cardiovascular risk factors (Serum Lipid Levels, Blood Pressure) and decreasing weight in adolescents with metabolic syndrome
- To evaluate the tolerability of a non-energy restricted very-low carbohydrate diet in these patients as measured by the SF-10 for Children, the Brief Symptom Inventory (BSI) and a scaled questionnaire regarding side effects.
- To compare two different maintenance programs in the group who receive the non- energy restricted very-low carbohydrate diet and compare each group to the group
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
West Virginia
-
Charleston, West Virginia, United States, 25302
- WVU Department of Pediatrics
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adolescents and young adults ages 13-18 with a BMI>95% for age or over 30 for young adults, with pre-existing metabolic syndrome
Exclusion Criteria:
- Subjects on any chronic medication other than antihistamines, asthma medications, oral contraceptives or diabetes medications, smoke more than 5 cigarettes/day, suffer from alcoholism or drug abuse or have any significant abnormality not associated with metabolic syndrome on screening labs will be excluded from randomization.
- Subjects currently taking Byetta will be excluded from the study, as a side effect of the drug is weight loss.
- Subjects with familial hypercholesteremia may be excluded if the investigator considers the history to be severe. The data collected from subjects with a HBA1C greater than 12.5 will be analyzed in a separate group, although they will still be randomized to one of the three treatment groups. This is due to the fact that past experience has shown that these individuals run a high risk of being non-compliant with medication use, diet, and exercise plans. Results from this group will be reported separately.
- Subjects who are pregnant or those desiring pregnancy will be excluded, as the safety of this intervention in pregnancy has not been established.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: energy restricted very-low carbohydrate
non-energy restricted ketogenic diet .
|
energy restricted very-low carbohydrate diet
|
|
Active Comparator: ADA diet
standard ADA diet
|
energy restricted very-low carbohydrate diet
standard ADA diet
|
|
Active Comparator: low glycemic index
restricted ketogenic diet
|
restricted ketogenic diet
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
weight loss
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Steven Sondike, MD, WVU Department of Pediatrics
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 06-02-1776
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Insulin Resistance
-
NCT01877551CompletedEndoplasmic Reticulum Stress | HIV Related Insulin Resistance | Protease Inhibitor Related Insulin Resistance
-
NCT06193668RecruitingLipid-induced Insulin Resistance
-
NCT07633704CompletedInsulin Sensitivity/Resistance
-
NCT00085982Active, not recruitingSevere Insulin Resistance
-
NCT04496388CompletedExercise, Insulin Resistance, Visceral Adipose Tissue
-
NCT06766617CompletedInsulin Sensitivity/Resistance
-
NCT07255807Not yet recruitingInsulin Sensitivity/Resistance | Metabolic Health
-
NCT04651842Completed
Clinical Trials on energy restricted very-low carbohydrate diet
-
NCT05049954Enrolling by invitationObesity | Metabolic Syndrome | Weight Loss | Ketogenic Dieting
-
NCT04943926RecruitingHypertension | Diabetes Mellitus, Type 2 | Insulin Resistance | Glucose Intolerance | Overweight and Obesity | Dyslipidemia Associated With Type II Diabetes Mellitus
-
NCT04082884Completed
-
NCT00616200CompletedDiarrhea Predominant Irritable Bowel Syndrome
-
NCT03221920UnknownDiet Modification | Colorectal Adenocarcinoma | Systemic Inflammation | Lactate | TNF Alpha
-
NCT03176056Completed
-
NCT03901014CompletedCholesterol Metabolism | Ketone Metabolism